Lupin Past Earnings Performance
Past criteria checks 5/6
Lupin has been growing earnings at an average annual rate of 39.4%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 5.3% per year. Lupin's return on equity is 16.9%, and it has net margins of 12.3%.
Key information
39.4%
Earnings growth rate
39.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 5.3% |
| Return on equity | 16.9% |
| Net Margin | 12.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Lupin Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Nov 10
With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case
Sep 17Lupin Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 09Unpleasant Surprises Could Be In Store For Lupin Limited's (NSE:LUPIN) Shares
Aug 01Lupin Limited (NSE:LUPIN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Jul 13Lupin's (NSE:LUPIN) Dividend Will Be Increased To ₹8.00
Jul 12These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely
Jun 15Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results
May 09With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case
May 08Investor Optimism Abounds Lupin Limited (NSE:LUPIN) But Growth Is Lacking
Apr 20Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly
Mar 03Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 10Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk
Jan 19Is Lupin (NSE:LUPIN) Using Too Much Debt?
Nov 10Is Lupin (NSE:LUPIN) Using Too Much Debt?
Jun 23Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly
Mar 24Lupin's (NSE:LUPIN) Dividend Is Being Reduced To ₹4.00
Jul 08Revenue & Expenses Breakdown
How Lupin makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 214,313 | 26,265 | 38,664 | 0 |
| 30 Jun 24 | 207,971 | 22,635 | 37,196 | 0 |
| 31 Mar 24 | 200,108 | 19,145 | 35,930 | 0 |
| 31 Dec 23 | 194,801 | 17,910 | 34,647 | 0 |
| 30 Sep 23 | 186,049 | 13,314 | 33,394 | 0 |
| 30 Jun 23 | 177,119 | 9,714 | 32,504 | 0 |
| 31 Mar 23 | 166,417 | 4,301 | 31,845 | 0 |
| 31 Dec 22 | 160,946 | -3,239 | 31,090 | 0 |
| 30 Sep 22 | 159,333 | 682 | 30,889 | 0 |
| 30 Jun 22 | 158,791 | -21,596 | 30,758 | 0 |
| 31 Mar 22 | 164,055 | -15,280 | 30,810 | 0 |
| 31 Dec 21 | 163,052 | -5,497 | 30,151 | 0 |
| 30 Sep 21 | 161,616 | -6,570 | 29,780 | 0 |
| 30 Jun 21 | 159,053 | 16,521 | 29,047 | 0 |
| 31 Mar 21 | 151,630 | 12,165 | 29,146 | 0 |
| 31 Dec 20 | 152,260 | 11,458 | 30,368 | 0 |
| 30 Sep 20 | 149,777 | -1,609 | 30,707 | 0 |
| 30 Jun 20 | 150,249 | -5,572 | 31,456 | 0 |
| 31 Mar 20 | 153,748 | -3,995 | 30,744 | 0 |
| 31 Dec 19 | 174,693 | -4,428 | 35,429 | 0 |
| 30 Sep 19 | 176,892 | 3,138 | 34,959 | 0 |
| 30 Jun 19 | 172,806 | 7,068 | 34,394 | 0 |
| 31 Mar 19 | 146,646 | 5,121 | 29,658 | 0 |
| 31 Dec 18 | 163,114 | -4,665 | 32,875 | 0 |
| 30 Sep 18 | 157,822 | -931 | 31,721 | 0 |
| 30 Jun 18 | 157,829 | 960 | 31,033 | 0 |
| 31 Mar 18 | 157,765 | 2,513 | 30,718 | 0 |
| 31 Dec 17 | 159,233 | 14,150 | 30,361 | 0 |
| 30 Sep 17 | 164,306 | 18,264 | 30,717 | 0 |
| 30 Jun 17 | 167,693 | 20,336 | 30,567 | 0 |
| 31 Mar 17 | 173,674 | 25,575 | 30,419 | 0 |
| 31 Dec 16 | 173,910 | 29,351 | 28,249 | 0 |
| 30 Sep 16 | 164,558 | 28,265 | 26,372 | 0 |
| 30 Jun 16 | 154,918 | 25,841 | 24,576 | 0 |
| 31 Mar 16 | 141,316 | 22,607 | 22,931 | 0 |
| 31 Dec 15 | 131,055 | 20,106 | 36,592 | 1,682 |
| 30 Sep 15 | 127,273 | 20,823 | 35,467 | 1,682 |
| 30 Jun 15 | 125,794 | 23,035 | 34,614 | 1,682 |
| 31 Mar 15 | 127,700 | 24,032 | 18,570 | 0 |
| 31 Dec 14 | 128,124 | 24,092 | 32,709 | 1,311 |
| 30 Sep 14 | 126,567 | 22,839 | 32,337 | 1,311 |
| 30 Jun 14 | 121,512 | 20,601 | 31,630 | 1,311 |
| 31 Mar 14 | 112,866 | 18,364 | 30,808 | 1,311 |
| 31 Dec 13 | 107,519 | 16,915 | 28,011 | 890 |
Quality Earnings: LUPIN has high quality earnings.
Growing Profit Margin: LUPIN's current net profit margins (12.3%) are higher than last year (7.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LUPIN's earnings have grown significantly by 39.4% per year over the past 5 years.
Accelerating Growth: LUPIN's earnings growth over the past year (97.3%) exceeds its 5-year average (39.4% per year).
Earnings vs Industry: LUPIN earnings growth over the past year (97.3%) exceeded the Pharmaceuticals industry 20%.
Return on Equity
High ROE: LUPIN's Return on Equity (16.9%) is considered low.